InvestorsHub Logo
Followers 7
Posts 5499
Boards Moderated 0
Alias Born 09/11/2013

Re: None

Tuesday, 05/23/2017 9:04:24 AM

Tuesday, May 23, 2017 9:04:24 AM

Post# of 146240
Has NNVC delivered on this?

October 2014

The Company estimates that this funding is sufficient to enable us to perform initial human clinical trials of our injectable FluCide™ drug candidate, as well as possibly to advance our DengueCide™ orphan drug candidate towards initial human clinical trials. As previously reported, our strong cash position has enabled us to restart our anti-Ebola drug development program in response to the current epidemic. The Company's estimates are based on its current rate of expenditure and also on certain approximate estimates for clinical development of its drug candidate as gleaned from discussions with various contract research organizations.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News